Edaravone
(Synonyms: 依达拉奉; MCI-186) 目录号 : GC12838
Edaravone是一种经典的自由基清除剂,作为有机小分子可穿越血脑屏障,为脑细胞提供保护。
Cas No.:89-25-8
Sample solution is provided at 25 µL, 10mM.
Edaravone, a classical free-radical scavenger, is an organic substance capable of crossing the blood-brain barrier and offering protection to brain cells[1]. Edaravone’s keto-enol tautomerism underpins its potent radical-scavenging activity, enabling Edaravone to neutralize both peroxyl radicals and peroxynitrite and thereby confer cell- and neuro-protective antioxidant effects[2]. Edaravone can also be used to treat digestive diseases, including acute liver injury, liver fibrosis[3].
In vitro, pretreatment with 500μM Edaravone to spiral ganglion neurons (SGNs) for 20min reversed glutamate-induced injury: cell numbers were restored, death was prevented, spindle morphology was preserved, and debris was cleared. When 500μM Edaravone was instead added at 2, 6, or 12h after the glutamate insult, protection declined with delay; administration within 2h (or sooner) gave maximal rescue, whereas later time points failed to reduce cell death effectively[4]. Treating Hepa 1-6 hepatoma cells with Edaravone (1-100µM) for 24h under cystine deprivation dose-dependently suppressed cell death and markedly reduced lactate dehydrogenase (LDH) leakage[5].
In vivo, in Sprague-Dawley rats subjected to middle cerebral artery occlusion (MCAO), intraperitoneal administration of Edaravone (3mg/kg) significantly reduced both infarct volume and post-ischemic hemorrhage, yielding a markedly lower hemorrhage-to-infarct ratio than in untreated controls (23.5% vs. 63.2%)[6]. In seven-day-old Wistar rats, daily intraperitoneal Edaravone (20mg/kg) for 14 days starting at hydrocephalus induction attenuated astrocyte activation and conferred partial protection against apoptotic cell death[7].
References:
[1] Huang M, Mo Y, Lei H, et al. Edaravone: A Possible Treatment for Acute Lung Injury. Int J Gen Med. 2024;17:3975-3986.
[2] Duranti E, Cordani N, Villa C. Edaravone: A Novel Possible Drug for Cancer Treatment?. Int J Mol Sci. 2024;25(3):1633.
[3] Lei H, Wang M, Huang M, et al. Edaravone in Digestive Diseases - A Narrative Review. Drug Des Devel Ther. 2025;19:5071-5084.
[4] Bai X, Zhang C, Chen A, et al. Protective Effect of Edaravone on Glutamate-Induced Neurotoxicity in Spiral Ganglion Neurons. Neural Plast. 2016;2016:4034218.
[5] Homma T, Kobayashi S, Sato H, et al. Edaravone, a free radical scavenger, protects against ferroptotic cell death in vitro. Exp Cell Res. 2019;384(1):111592.
[6] Okamura K, Tsubokawa T, Johshita H, et al. Edaravone, a free radical scavenger, attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia. Neurol Res. 2014;36(1):65-69.
[7] Garcia CAB, Catalão CHR, Machado HR, et al. Edaravone reduces astrogliosis and apoptosis in young rats with kaolin-induced hydrocephalus. Childs Nerv Syst. 2017;33(3):419-428.
Edaravone是一种经典的自由基清除剂,作为有机小分子可穿越血脑屏障,为脑细胞提供保护[1]。Edaravone的酮-烯醇互变异构特性使其能高效清除过氧自由基和过氧亚硝酸盐,从而发挥细胞及神经抗氧化保护作用[2]。此外,Edaravone还可用于治疗包括急性肝损伤、肝纤维化在内的消化系统疾病[3]。
在体外,提前用500μM的Edaravone处理螺旋神经节神经元(SGNs)20分钟,可完全逆转谷氨酸诱导的损伤:细胞数量恢复、死亡被抑制、梭形形态保持、碎片清除;若在谷氨酸损伤后2、6或12小时才给予500μM的Edaravone,则保护效果随延迟而减弱,2小时内(或更早)给药效果最好,更晚给药则无法有效减少细胞死亡[4]。在胱氨酸剥夺条件下,用1-100μM的Edaravone处理Hepa 1-6肝癌细胞24小时,可剂量依赖性地抑制细胞死亡并显著减少乳酸脱氢酶(LDH)漏出[5]。
在体内,大脑中动脉闭塞(MCAO)模型Sprague-Dawley大鼠腹腔注射Edaravone(3mg/kg)后,梗死体积和缺血后出血量均显著减少,出血/梗死比明显低于未处理对照(23.5% vs 63.2%)[6]。在7日龄Wistar大鼠中,从脑积水诱导当天开始每日腹腔注射Edaravone(20mg/kg)连续14天,可显著抑制星形胶质细胞激活,并对凋亡性细胞死亡产生部分保护作用[7]。
Cell experiment [1]: | |
Cell lines | Spiral ganglion neurons (SGNs) |
Preparation Method | SGNs (1.0×105/mL) subcultured in 96-well or 24-well plates were treated with 2mM glutamate for 10 minutes. Then the medium was replaced by normal DMEM. Different concentrations of Edaravone were added to the medium either 20min before or 2h, 6h, and 12h after glutamate treatment. Then the medium was changed to normal medium 10min after that. Cell viability was observed after normal culture for 24h. |
Reaction Conditions | 250, 500, and 750μM; 20min (for preventative effect), 22h, 18h, 12h (therapeutic effect) |
Applications | Edaravone pretreatment reversed the glutamate-induced damage: Edaravone restored cell numbers, prevented widespread death, maintained the neurons’ elongated spindle shape, and eliminated cellular debris. At 500μM and 750μM, SGNs grew normally with virtually no cell loss. 500μM Edaravone was added to the medium 2h, 6h, or 12h after glutamate treatment. Cell death decreased with the treatment of Edaravone. 2h after glutamate treatment or even an earlier time point was the most suitable time point for administering Edaravone to reach the maximal protection effect among these groups. At later time points, the cell death could not be reduced effectively. |
Animal experiment [2]: | |
Animal models | Sprague-Dawley rats |
Preparation Method | Adult male Sprague-Dawley rats weighing between 275 and 415g were randomly divided into the following two groups, with 10 animals in each group: middle cerebral artery occlusion (MCAO) treated with Edaravone and MCAO treated with physiological saline (controls; n=10). Rats in which MCAO was performed/rats with hyperglycemia, were administered Edaravone. Edaravone was dissolved in 1N NaOH, and the pH of the solution was adjusted to 7.0 using 1N HCl. Edaravone (3mg/kg) was IP injected immediately after occlusion, and the injection was repeated twice, once immediately following reperfusion and 1 hour after reperfusion. |
Dosage form | 3mg/kg; i.p. |
Applications | Edaravone significantly decreased infarct volume, with the average infarct volume in the Edaravone-treated rats (227.6mm3) being significantly lower than that in the control rats (264.0mm3). Edaravone treatment also decreased the postischemic hemorrhage volumes (53.4mm3 in Edaravone-treated rats vs 176.4mm3 in controls). In addition, the ratio of hemorrhage volume to infarct volume was lower in the Edaravone-treated rats (23.5%) than in the untreated rats (63.2%). |
References:
[1] Bai X, Zhang C, Chen A, et al. Protective Effect of Edaravone on Glutamate-Induced Neurotoxicity in Spiral Ganglion Neurons. Neural Plast. 2016;2016:4034218.
[2] Okamura K, Tsubokawa T, Johshita H, et al. Edaravone, a free radical scavenger, attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia. Neurol Res. 2014;36(1):65-69.
Cas No. | 89-25-8 | SDF | |
别名 | 依达拉奉; MCI-186 | ||
化学名 | 5-methyl-2-phenyl-4H-pyrazol-3-one | ||
Canonical SMILES | CC1=NN(C(=O)C1)C2=CC=CC=C2 | ||
分子式 | C10H10N2O | 分子量 | 174.2 |
溶解度 | ≥ 6.45mg/mL in DMSO, ≥ 47.8 mg/mL in EtOH with ultrasonic | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 5.7405 mL | 28.7026 mL | 57.4053 mL |
5 mM | 1.1481 mL | 5.7405 mL | 11.4811 mL |
10 mM | 0.5741 mL | 2.8703 mL | 5.7405 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet